Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomic regions: data from phase 3 clinical trials.
Moderate-to-severe atopic dermatitis (AD) can affect different parts of the body, and some adults have more localized AD, such as face and neck involvement. Compared with non-exposed areas, such as the trunk, exposed areas such as the face, neck, and hands could be more vulnerable to environmental allergens and irritants and can be more refractory to topical therapies. Local adverse effects of topical therapies are more likely to occur on the face and neck. Additional pathologies, such as contact dermatitis, could complicate the clinical picture and response of exposed areas to treatment. Microbial factors (e.g. Malassezia) in specific regions may also influence AD severity on the face and neck.